Clinical effectiveness of HPV vaccine by age at vaccination: a matched case-control study
Oliveira C, Shapiro E, Sheth S, Ellingson M, Johnson N, Sullivan E, Querec T, Unger E, Niccolai L. Clinical effectiveness of HPV vaccine by age at vaccination: a matched case-control study. The Lancet Regional Health - Americas 2025, 51: 101225. PMID: 41019517, PMCID: PMC12465035, DOI: 10.1016/j.lana.2025.101225.Peer-Reviewed Original ResearchHPV vaccinationCase-control studyHuman papillomavirusVaccine effectivenessClinical effectsDose of HPV vaccineHigh-grade cervical lesionsOdds ratioBenefits of HPV vaccinationEffectiveness of HPV vaccinationMultivariable conditional logistic regression modelsVaccine-eligible womenPap smear resultsHuman papillomavirus vaccineConfidence intervalsConditional logistic regression modelsCenters for Disease Control and PreventionDisease Control and PreventionCervical lesionsSmear resultsFirst doseHPV-16Pap testControl and PreventionLogistic regression modelsEstimated Effectiveness of Nirsevimab Against Respiratory Syncytial Virus
Xu H, Aparicio C, Wats A, Araujo B, Pitzer V, Warren J, Shapiro E, Niccolai L, Weinberger D, Oliveira C. Estimated Effectiveness of Nirsevimab Against Respiratory Syncytial Virus. JAMA Network Open 2025, 8: e250380. PMID: 40063022, PMCID: PMC11894488, DOI: 10.1001/jamanetworkopen.2025.0380.Peer-Reviewed Original ResearchConceptsRSV-positive casesCase-control studyRSV infectionLRTI-associated hospitalizationsWeeks postimmunizationLong-acting monoclonal antibodiesTest-negative case-control studyClinical settingRespiratory syncytial virusMultivariate logistic regressionYale New Haven Health SystemRSV diseaseEmergency department dataState immunization registryRSV seasonSyncytial virusNirsevimabPolymerase chain reactionClinical trialsLRTIInfantsPotential confoundersMonoclonal antibodiesBroader outcomesDisease severity
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply